← Return to Intraductal Prostate Cancer: Any info about recurrence rates?

Discussion

Intraductal Prostate Cancer: Any info about recurrence rates?

Prostate Cancer | Last Active: 3 days ago | Replies (25)
Comment receiving replies
@ddl

I think things vary from person to person, but take a look at the STAMPEDE study. It seems to say that Abiraterone added to ADT earlier improved overall survival and metastasis free survival.

Jump to this post

Replies to "I think things vary from person to person, but take a look at the STAMPEDE study...."
jeffmarc | @jeffmarc | 3 days ago

These people started off with a PSA with an average of 53.

I started on Zytiga, but not until after Lupron Failed, and Zytiga gave me 2.5 extra years after that. My PSA was 1.2 when I started Abbie.

The thing is drugs like Zytiga don’t work forever. I had to quit because it caused me heart issues. Other people I know have quit because it failed, and their PSA started rising.

Maybe taking it along with ADT could just be most beneficial when you have a high PSA, or when it is locally advanced or metastatic as the stampede trial says.

VIEW AND REPLY